About Mark Worscheh
Mark Worscheh is a chief financial officer and director at Goldenrod Therapeutics.
Form D filings also name Mark Worscheh as a director at Pulmotect.
Mark Worscheh first appears on SEC filings in 2016.
Experience
This experience comes from SEC filings. The years are when the filings name Mark Worscheh in the role, so the role may have started earlier or lasted longer.
Goldenrod Therapeutics, Inc.
Chief Financial Officer and director
2026 · Houston, TX
Develops medicines for people with neurological diseases, initially targeting Friedreich’s ataxia.
Key Colleagues at Startups
The people Mark Worscheh works with at each company, as listed on that company's latest Form D.
Goldenrod Therapeutics, Inc. · Form D, Jun 3, 2026
Dev Chatterjee
Chief Executive Officer
LI
Leo Linbeck IV
Executive officer
Atul Varadhachary
President and director
LI
Leo Linbeck III
Director
TB
Thomas Brenninkmeijer
Director
Pulmotect, Inc. · Form D, May 6, 2016
BS
Brenton Scott
President
BG
Bruce Given
Director
MH
Magnus Hook
Director
Atul Varadhachary
Director
LI
Leo Linbeck III
Director